HC2 Holdings Reports Fourth Quarter and Full Year 2020 Results
- Fourth Quarter 2020 Consolidated Net Revenue of
- Strategic Focus Sharpened on Growth in Infrastructure, Life Sciences and Spectrum -
- Capital Structure Enhanced Through Rights Offering and Debt Refinancing -
Financial Summary | |||||||||||||||||||||
(in millions, except per share amounts) | Three Months Ended |
Twelve Months Ended |
|||||||||||||||||||
2020 | 2019 | Increase / (Decrease) |
2020 | 2019 | Increase / (Decrease) |
||||||||||||||||
Net revenue | $ | 251.8 | $ | 247.6 | 1.7 | % | $ | 1,005.8 | $ | 1,077.0 | (6.6 | )% | |||||||||
Net loss attributable to common stock and participating preferred stockholders |
$ | (7.1 | ) | $ | (31.4 | ) | (77.4 | )% | $ | (95.6 | ) | $ | (31.5 | ) | 203.5 | % | |||||
Loss per share - Net loss attributable to common stock and participating preferred stockholders |
$ | (0.11 | ) | $ | (0.70 | ) | (84.3 | )% | $ | (1.88 | ) | $ | (0.70 | ) | 168.6 | % | |||||
Total Adjusted EBITDA | $ | 10.0 | $ | 16.0 | (37.5 | )% | $ | 25.5 | $ | 43.4 | (41.2 | )% | |||||||||
(1) Reconciliation of GAAP to Non-GAAP measures follows. | |||||||||||||||||||||
(2) Note that Total Adjusted EBITDA excludes results for HC2's Insurance segment. | |||||||||||||||||||||
Commentary
"The new HC2 has a sharpened strategic focus on the three key business areas which we believe will drive growth and increased stakeholder value: Infrastructure, Life Sciences and Spectrum,” stated
"We have also reached a milestone in terms of the financial position of HC2," added
- Sharpened strategic focus. HC2 sharpened its focus on three key business areas that the Company believes will drive growth and generate stakeholder value in 2021 and beyond: Infrastructure, Life Sciences and Spectrum. The Company accomplished this through the disposition of the Marine and Telecommunications businesses and the sale of several non-core broadcast stations within our Spectrum segment during 2020, and the sale of the Clean Energy business in early 2021 (see below). In aggregate, HC2 has reduced its number of operating segments from seven to four through these portfolio optimization initiatives. Additionally, the Board of Directors continues to evaluate the Insurance segment and the previously disclosed non-binding indication of interest for the Insurance business (see below).
- Enhanced capital structure. HC2 took several additional steps to enhance the Company's capital structure, including a rights offering in
November 2020 and the refinancing of holding company debt inFebruary 2021 . Combined with the completed asset sales, HC2 reduced overall indebtedness, lowered its cost of capital, obtained additional liquidity and flexibility, and maintains no near-term holding company debt maturities. - Lowered corporate costs. HC2 management reduced recurring corporate expenses by approximately 13% for the year through decreased compensation and occupancy costs.
- Business execution. Throughout an uncertain period, each of HC2's three focus businesses is executing well in different ways, showing resiliency in the case of Infrastructure, making measurable progress toward product commercialization in the case of Life Sciences, and completing the station build-out and reducing costs in the case of Spectrum.
Fourth Quarter 2020 Highlights
- HC2 completed the previously-announced common stock rights offering, generating
$65 million in gross proceeds ($61 .5 million, net of dealer management fees and other offering expenses) consisting of the issuance of 28.7 million shares of common stock at a price of$2.27 per share. - HC2 completed the previously-announced sale of its Telecommunications subsidiary,
PTGi International Carrier Services, Inc. , generating a net gain of$0 .9 million. The segment's operating results are presented as discontinued operations in the attached tables and are excluded from the discussion of results from continuing operations for the comparable periods. - HC2 received a non-binding indication of interest for the potential acquisition of its Insurance segment from
Continental General Holdings LLC , an entity controlled byMichael Gorzynski , a director of the Company and beneficial owner of approximately 6.6% of the Company's outstanding stock, for a potential transaction value of approximately$90 million , subject to certain adjustments, consisting of, among other things, a combination of$65 million in cash and the transfer to HC2 (or the cancellation) and/or modification of the terms of certain HC2 and HC2-affiliate securities owned by the Insurance company.
Subsequent Events
- In
January 2021 , HC2 completed the sale of majority-owned Clean Energy subsidiaryBeyond6, Inc. toMercuria Investments US, Inc. for approximately$169 million . HC2, which owned 61% of Beyond6 on a fully diluted basis, received$70 million in net proceeds. The Clean Energy segment's operating results are presented as discontinued operations in the attached tables, and are excluded from the discussion of the Company's results from continuing operations for the comparable periods. - In
February 2021 , HC2 completed a$330 .0 million offering of 8.5% senior secured notes due 2026, which was used to retire the existing 11.5% senior secured notes due 2021 and repay the outstanding indebtedness under its revolving credit agreement. As part of the refinancing of the senior secured notes, HC2 entered into exchange agreements with certain holders of$51 .8 million of the outstanding 7.5% convertible senior notes, extending the maturity date toAugust 1, 2026 . - In
February 2021 , HC2 amended its revolving credit facility, extending the maturity fromSeptember 2021 toFebruary 2024 , increasing the maximum credit commitment from$15 million to$20 million , lowering the current borrowing rate under the agreement by 100 basis points, and updating certain affirmative and negative covenants. The Company applied part of the proceeds of the senior secured notes offering to repay all outstanding indebtedness under the credit facility, and currently has no borrowings under the credit facility.
Fourth Quarter and Full Year Financial Highlights
- Net Revenue: For the fourth quarter of 2020, HC2 consolidated net revenue was
$251.8 million , an increase of 1.7% compared to$247.6 million for the prior year quarter. Higher revenue from Infrastructure was partially offset by lower revenues from Insurance and Spectrum, net of eliminations. For the full year 2020, consolidated net revenue was$1,005.8 million compared to$1,077.0 million in 2019.
NET REVENUE by OPERATING SEGMENT | ||||||||||||||||||||||||
(in millions) | Three Months Ended |
Twelve Months Ended |
||||||||||||||||||||||
2020 | 2019 | Increase / (Decrease) |
2020 | 2019 | Increase / (Decrease) |
|||||||||||||||||||
Infrastructure | $ | 167.0 | $ | 157.1 | $ | 9.9 | $ | 676.6 | $ | 713.3 | $ | (36.7 | ) | |||||||||||
Insurance | 77.0 | 80.3 | (3.3 | ) | 300.2 | 331.6 | (31.4 | ) | ||||||||||||||||
Spectrum | 11.0 | 12.0 | (1.0 | ) | 40.3 | 41.8 | (1.5 | ) | ||||||||||||||||
Other | — | 0.5 | (0.5 | ) | — | 0.5 | (0.5 | ) | ||||||||||||||||
Eliminations (1) | (3.2 | ) | (2.3 | ) | (0.9 | ) | (11.3 | ) | (10.2 | ) | (1.1 | ) | ||||||||||||
Consolidated HC2 | $ | 251.8 | $ | 247.6 | $ | 4.2 | $ | 1,005.8 | $ | 1,077.0 | $ | (71.2 | ) | |||||||||||
(1) The Insurance segment revenues are inclusive of realized and unrealized gains and net investment income for the three and twelve months ended |
- Net Income (Loss): For the fourth quarter of 2020, HC2 reported a Net Loss attributable to common stock and participating preferred stockholders of
$7.1 million , or$(0.11) per share, compared to a Net Loss of$31.4 million , or$(0.70) per share, for the prior year quarter. For the full year 2020, Net Loss attributable to common and participating preferred stockholders was$95.6 million , or$(1.88) per fully diluted share, compared to a Net Loss of$31.5 million , or$(0.70) per fully diluted share, in the full year 2019.
NET INCOME (LOSS) by OPERATING SEGMENT | ||||||||||||||||||||||||
(in millions) | Three Months Ended |
Twelve Months Ended |
||||||||||||||||||||||
2020 | 2019 | Increase / (Decrease) |
2020 | 2019 | Increase / (Decrease) |
|||||||||||||||||||
Infrastructure | $ | 2.8 | $ | 6.7 | $ | (3.9 | ) | $ | 6.8 | $ | 24.7 | $ | (17.9 | ) | ||||||||||
Insurance | 16.1 | (15.2 | ) | 31.3 | 40.2 | 59.4 | (19.2 | ) | ||||||||||||||||
Life Sciences | (5.7 | ) | (1.8 | ) | (3.9 | ) | (14.4 | ) | (0.2 | ) | (14.2 | ) | ||||||||||||
Spectrum | 9.1 | (4.4 | ) | 13.5 | (17.5 | ) | (18.5 | ) | 1.0 | |||||||||||||||
Other and Eliminations | (6.2 | ) | 2.4 | (8.6 | ) | (1.5 | ) | (0.6 | ) | (0.9 | ) | |||||||||||||
Non-operating Corporate | (19.9 | ) | (17.6 | ) | (2.3 | ) | (99.6 | ) | (87.6 | ) | (12.0 | ) | ||||||||||||
Consolidating Eliminations attributable to HC2 Holdings Insurance Segment(1) |
(0.9 | ) | (1.1 | ) | 0.2 | (6.0 | ) | (8.7 | ) | 2.7 | ||||||||||||||
Net loss attributable to |
$ | (4.7 | ) | $ | (31.0 | ) | $ | 26.3 | $ | (92.0 | ) | $ | (31.5 | ) | $ | (60.5 | ) | |||||||
Less: Preferred dividends, deemed dividends, and repurchase gains |
2.4 | 0.4 | 2.0 | 3.6 | — | 3.6 | ||||||||||||||||||
Net loss attributable to common stock and participating preferred stockholders |
$ | (7.1 | ) | $ | (31.4 | ) | $ | 24.3 | $ | (95.6 | ) | $ | (31.5 | ) | $ | (64.1 | ) | |||||||
(1) The Insurance segment results are inclusive of realized and unrealized gains and net investment income for the three and twelve months ended |
||||||||||||||||||||||||
- Adjusted EBITDA: For the fourth quarter of 2020, Total Adjusted EBITDA, which excludes the Insurance segment, totaled
$10.0 million , compared to$16.0 million for the prior year quarter. Improvement at Spectrum was more than offset by decreased contribution from Infrastructure, increased losses at Life Sciences, and higher Non-operating Corporate expenses. For the full year 2020, Total Adjusted EBITDA, excluding Insurance, was$25.5 million , compared to$43.4 million in 2019.
ADJUSTED EBITDA by OPERATING SEGMENT | |||||||||||||||||||||||
(in millions) | Three Months Ended |
Twelve Months Ended |
|||||||||||||||||||||
2020 | 2019 | Increase / (Decrease) |
2020 | 2019 | Increase / (Decrease) |
||||||||||||||||||
Infrastructure | $ | 17.4 | $ | 20.8 | $ | (3.4 | ) | $ | 63.2 | $ | 75.7 | $ | (12.5 | ) | |||||||||
Life Sciences | (7.9 | ) | (3.1 | ) | (4.8 | ) | (22.5 | ) | (11.8 | ) | (10.7 | ) | |||||||||||
Spectrum | 1.1 | (1.0 | ) | 2.1 | (1.2 | ) | (6.3 | ) | 5.1 | ||||||||||||||
Other and Eliminations | 2.7 | 2.0 | 0.7 | 1.6 | 3.7 | (2.1 | ) | ||||||||||||||||
Non-operating Corporate | (3.3 | ) | (2.7 | ) | (0.6 | ) | (15.6 | ) | (17.9 | ) | 2.3 | ||||||||||||
Total Adjusted EBITDA | $ | 10.0 | $ | 16.0 | $ | (6.0 | ) | $ | 25.5 | $ | 43.4 | $ | (17.9 | ) |
- Balance Sheet: As of
December 31, 2020 , HC2 had consolidated cash, cash equivalents and investments of$4 .9 billion, which includes cash and investments associated with HC2’s Insurance segment. Excluding the Insurance segment, consolidated cash was$43.8 million , of which$27.5 million was at the HC2 corporate level.
Fourth Quarter and Full Year 2020 Segment Highlights
- Infrastructure
– | ||
– | For the fourth quarter of 2020, DBM reported net revenue of |
|
– | DBM's total backlog was approximately |
- Life Sciences
– | Through Pansend Life Sciences, HC2 is strategically focused on the development of innovative technologies and products in the healthcare industry and is currently invested in four companies. The investments with the greatest potential for value creation in the near-term are |
|
– | R2 is actively taking pre-orders for Glacial RX™, its FDA-approved device utilizing patented CryoAesthetic technology, and is experiencing strong early demand from |
|
– | MediBeacon received a commitment from Huadong for an additional |
- Spectrum
– | ||
– | For the fourth quarter of 2020, |
|
– | For the fourth quarter of 2020, |
|
– | During the fourth quarter of 2020, |
|
– | As of early |
- Insurance
– | As previously announced, HC2 received a non-binding indication of interest for the potential acquisition of its Insurance segment from |
|
– | As of |
|
– | For the fourth quarter of 2020, the Insurance segment reported Net Income of |
|
– | Pre-Tax Insurance AOI was |
Conference Call
HC2 will host a live conference call to discuss its fourth quarter and full year 2020 financial results and operations today at
- Live Webcast and Call. A live webcast of the conference call can be accessed by interested parties through the Investor Relations section of the HC2 website at ir.hc2.com.
– Dial-in: 1-877-705-6003 (Domestic Toll Free) / 1-201-493-6725 (International)
– Participant Entry Number: 13717091
- Conference Replay*
– Dial-in: 1-844-512-2921 (Domestic Toll Free) / 1-412-317-6671 (International)
– Conference Number: 13717091
*Available approximately two hours after the end of the conference call through
About HC2
Contacts
Investor Contact:
FNK IR
ir@hc2.com
(212) 235-2691
Media Contact:
Reevemark
HC2@reevemark.com
(212) 433-4600
Non-GAAP Financial Measures
In this press release, HC2 refers to certain financial measures that are not presented in accordance with
Adjusted EBITDA
Management believes that Adjusted EBITDA provides investors with meaningful information for gaining an understanding of our results as it is frequently used by the financial community to provide insight into an organization’s operating trends and facilitates comparisons between peer companies, since interest, taxes, depreciation, amortization and the other items listed in the definition of Adjusted EBITDA below can differ greatly between organizations as a result of differing capital structures and tax strategies. Adjusted EBITDA can also be a useful measure of a company’s ability to service debt. While management believes that non-
The calculation of Adjusted EBITDA, as defined by us, consists of Net income (loss) as adjusted for depreciation and amortization; Other operating (income) expense, which is inclusive of (gain) loss on sale or disposal of assets, lease termination costs, and
Management recognizes that using Adjusted EBITDA as a performance measure has inherent limitations as an analytical tool as compared to net income (loss) or other GAAP financial measures, as these non-GAAP measures exclude certain items, including items that are recurring in nature, which may be meaningful to investors.
Adjusted Operating Income - Insurance
Adjusted Operating Income (“Insurance AOI”) and Pre-tax Adjusted Operating Income (“Pre-tax Insurance AOI”) for the Insurance segment are non-U.S. GAAP financial measures frequently used throughout the insurance industry and are economic measures the Insurance segment uses to evaluate its financial performance. Management believes that Insurance AOI and Pretax Insurance AOI measures provide investors with meaningful information for gaining an understanding of certain results and provide insight into an organization’s operating trends and facilitates comparisons between peer companies. However, Insurance AOI and Pre-tax Insurance AOI have certain limitations, and we may not calculate it the same as other companies in our industry. It should, therefore, be read together with the Company's results calculated in accordance with
Similarly to Adjusted EBITDA, using Insurance AOI and Pre-tax Insurance AOI as performance measures have inherent limitations as an analytical tool as compared to income (loss) from operations or other
Management defines Insurance AOI as Net income (loss) for the Insurance segment adjusted to exclude the impact of net investment gains (losses), including OTTI losses recognized in operations; asset impairment; intercompany elimination; bargain purchase gains; reinsurance gains; and acquisition costs. Management defines Pre-tax Insurance AOI as Insurance AOI adjusted to exclude the impact of income tax (benefit) expense recognized during the current period. Management believes that Insurance AOI and Pre-tax Insurance AOI provide meaningful financial metrics that help investors understand certain results and profitability. While these adjustments are an integral part of the overall performance of the Insurance segment, market conditions impacting these items can overshadow the underlying performance of the business. Accordingly, we believe using a measure which excludes their impact is effective in analyzing the trends of our operations.
Cautionary Statement Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release contains, and certain oral statements made by our representatives from time to time may contain, forward-looking statements, including, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses of the government and HC2 on our business, financial condition and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. Generally, forward-looking statements include information describing actions, events, results, strategies and expectations and are generally identifiable by use of the words “believes,” “expects,” “intends,” “anticipates,” “plans,” “seeks,” “estimates,” “projects,” “may,” “will,” “could,” “might,” or “continues” or similar expressions. The forward-looking statements in this press release include, without limitation, any statements regarding our expectations regarding entering definitive agreements in respect of and consummating potential divestitures of any of our subsidiaries, reducing debt and related interest expense at the holding company level with the net proceeds of such divestitures, building shareholder value, future cash flow, longer-term growth and invested assets, the severity, magnitude and duration of the COVID-19 pandemic, including impacts of the pandemic and of businesses’ and governments’ responses to the pandemic on HC2’s operations and personnel, and on commercial activity and demand across our businesses, HC2’s inability to predict the extent to which the COVID-19 pandemic and related impacts will continue to adversely impact HC2’s business operations, financial performance, results of operations, financial position, the prices of HC2’s securities and the achievement of HC2’s strategic objectives, and changes in macroeconomic and market conditions and market volatility (including developments and volatility arising from the COVID-19 pandemic), including interest rates, the value of securities and other financial assets, and the impact of such changes and volatility on HC2’s financial position. Such statements are based on the beliefs and assumptions of HC2’s management and the management of HC2’s subsidiaries and portfolio companies.
The Company believes these judgments are reasonable, but you should understand that these statements are not guarantees of performance or results, and the Company’s actual results could differ materially from those expressed or implied in the forward-looking statements due to a variety of important factors, both positive and negative, that may be revised or supplemented in subsequent statements and reports filed with the
Although HC2 believes its expectations and assumptions regarding its future operating performance are reasonable, there can be no assurance that the expectations reflected herein will be achieved. There can be no assurance that definitive agreements for potential divestitures or other strategic transactions will be entered into with respect to any of our subsidiaries, that any such transactions will be consummated, or the timing, terms, conditions or net proceeds thereof. These risks and other important factors discussed under the caption “Risk Factors” in our most recent Annual Report on Form 10-K filed with the
You should not place undue reliance on forward-looking statements. All forward-looking statements attributable to HC2 or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. All such statements speak only as of the date made, and unless legally required, HC2 undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in millions, except per share amounts) |
|||||||||||||||
(Unaudited) | (Audited) | ||||||||||||||
Three Months Ended |
Twelve Months Ended |
||||||||||||||
2020 | 2019 | 2020 | 2019 | ||||||||||||
Revenue | $ | 178.0 | $ | 169.4 | $ | 716.9 | $ | 755.6 | |||||||
Life, accident and health earned premiums, net | 28.3 | 28.3 | 115.1 | 116.9 | |||||||||||
Net investment income | 41.8 | 51.3 | 188.9 | 203.8 | |||||||||||
Net realized and unrealized gains (losses) on investments | 3.7 | (1.4 | ) | (15.1 | ) | 0.7 | |||||||||
Net revenue | 251.8 | 247.6 | 1,005.8 | 1,077.0 | |||||||||||
Operating expenses | |||||||||||||||
Cost of revenue | 140.8 | 129.4 | 588.5 | 596.0 | |||||||||||
Policy benefits, changes in reserves, and commissions | 55.0 | 67.6 | 250.0 | 234.5 | |||||||||||
Selling, general and administrative | 44.5 | 42.7 | 181.1 | 177.3 | |||||||||||
Depreciation and amortization | (0.7 | ) | 0.5 | (3.2 | ) | (0.9 | ) | ||||||||
Asset impairment expense | 2.5 | 47.6 | 13.5 | 50.0 | |||||||||||
Other operating (income) expense | (16.3 | ) | 0.2 | (20.0 | ) | (5.2 | ) | ||||||||
Total operating expenses | 225.8 | 288.0 | 1,009.9 | 1,051.7 | |||||||||||
Income (loss) from operations | 26.0 | (40.4 | ) | (4.1 | ) | 25.3 | |||||||||
Interest expense | (19.9 | ) | (19.9 | ) | (79.4 | ) | (76.1 | ) | |||||||
Loss on early extinguishment or restructuring of debt | (0.2 | ) | — | (9.4 | ) | — | |||||||||
Income (loss) from equity investees | 0.6 | 1.6 | (3.4 | ) | 1.6 | ||||||||||
Gain on bargain purchase | — | — | — | 1.1 | |||||||||||
Other (expense) income | (4.0 | ) | 2.1 | 68.5 | 6.3 | ||||||||||
Income (loss) from continuing operations | 2.5 | (56.6 | ) | (27.8 | ) | (41.8 | ) | ||||||||
Income tax (expense) benefit | (6.2 | ) | 25.6 | (10.5 | ) | 19.6 | |||||||||
Loss from continuing operations | (3.7 | ) | (31.0 | ) | (38.3 | ) | (22.2 | ) | |||||||
Loss (income) from discontinued operations | (4.3 | ) | 0.3 | (63.8 | ) | (13.9 | ) | ||||||||
Net loss | (8.0 | ) | (30.7 | ) | (102.1 | ) | (36.1 | ) | |||||||
Net loss (income) attributable to noncontrolling interest and redeemable noncontrolling interest |
3.3 | (0.3 | ) | 10.1 | 4.6 | ||||||||||
Net loss attributable to |
(4.7 | ) | (31.0 | ) | (92.0 | ) | (31.5 | ) | |||||||
Less: Preferred dividends, deemed dividends, and repurchase gains | 2.4 | 0.4 | 3.6 | — | |||||||||||
Net loss attributable to common stock and participating preferred stockholders |
$ | (7.1 | ) | $ | (31.4 | ) | $ | (95.6 | ) | $ | (31.5 | ) | |||
Loss per common share - continuing operations | |||||||||||||||
Basic | $ | (0.03 | ) | $ | (0.66 | ) | $ | (0.94 | ) | $ | (0.40 | ) | |||
Diluted | $ | (0.03 | ) | $ | (0.66 | ) | $ | (0.94 | ) | $ | (0.40 | ) | |||
Loss per common share - discontinued operations | |||||||||||||||
Basic | $ | (0.08 | ) | $ | (0.04 | ) | $ | (0.94 | ) | $ | (0.30 | ) | |||
Diluted | $ | (0.08 | ) | $ | (0.04 | ) | $ | (0.94 | ) | $ | (0.30 | ) | |||
Loss per share - Net loss attributable to common stock and participating preferred stockholders |
|||||||||||||||
Basic | $ | (0.11 | ) | $ | (0.70 | ) | $ | (1.88 | ) | $ | (0.70 | ) | |||
Diluted | $ | (0.11 | ) | $ | (0.70 | ) | $ | (1.88 | ) | $ | (0.70 | ) | |||
Weighted average common shares outstanding: | |||||||||||||||
Basic | 61.2 | 45.0 | 50.3 | 44.8 | |||||||||||
Diluted | 62.5 | 45.0 | 50.7 | 44.8 |
HC2 HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEET (in millions, except share amounts) (Audited) |
||||||||
2020 |
2019 |
|||||||
Assets | ||||||||
Investments: | ||||||||
Fixed maturity securities, available-for-sale at fair value | $ | 4,456.1 | $ | 4,028.9 | ||||
Equity securities | 77.3 | 92.5 | ||||||
Mortgage loans | 57.2 | 183.5 | ||||||
Policy loans | 17.8 | 19.1 | ||||||
Other invested assets | 57.2 | 68.1 | ||||||
Total investments | 4,665.6 | 4,392.1 | ||||||
Cash and cash equivalents | 232.3 | 193.7 | ||||||
Accounts receivable, net | 184.7 | 228.9 | ||||||
Recoverable from reinsurers | 957.5 | 953.7 | ||||||
Deferred tax asset | 4.4 | 2.8 | ||||||
Property, plant and equipment, net | 113.9 | 129.5 | ||||||
111.0 | 110.4 | |||||||
Intangibles, net | 174.6 | 210.6 | ||||||
Assets held for sale | 126.4 | 555.2 | ||||||
Other assets | 172.4 | 181.4 | ||||||
Total assets | $ | 6,742.8 | $ | 6,958.3 | ||||
Liabilities, temporary equity and stockholders’ equity | ||||||||
Life, accident and health reserves | $ | 4,627.5 | $ | 4,567.1 | ||||
Annuity reserves | 228.8 | 236.4 | ||||||
Value of business acquired | 199.8 | 221.1 | ||||||
Accounts payable and other current liabilities | 176.3 | 190.6 | ||||||
Deferred tax liability | 142.3 | 81.6 | ||||||
Debt obligations | 561.5 | 723.9 | ||||||
Liabilities held for sale | 74.7 | 334.9 | ||||||
Other liabilities | 116.0 | 137.5 | ||||||
Total liabilities | 6,126.9 | 6,493.1 | ||||||
Commitments and contingencies | ||||||||
Temporary equity | ||||||||
Preferred stock | 10.4 | 10.3 | ||||||
Redeemable noncontrolling interest | 5.3 | 11.3 | ||||||
Total temporary equity | 15.7 | 21.6 | ||||||
Stockholders’ equity | ||||||||
Common stock, |
0.1 | — | ||||||
Shares authorized: 160,000,000 and 80,000,000 at |
||||||||
Shares issued: 77,836,586 and 46,810,676 at |
||||||||
Shares outstanding: 76,726,835 and 46,067,852 at |
||||||||
Additional paid-in capital | 355.7 | 281.1 | ||||||
(4.2 | ) | (3.3 | ) | |||||
Accumulated deficit | (188.7 | ) | (96.7 | ) | ||||
Accumulated other comprehensive income (loss) | 396.9 | 168.7 | ||||||
559.8 | 349.8 | |||||||
Noncontrolling interest | 40.4 | 93.8 | ||||||
Total stockholders’ equity | 600.2 | 443.6 | ||||||
Total liabilities, temporary equity and stockholders’ equity | $ | 6,742.8 | $ | 6,958.3 | ||||
RECONCILIATION OF NET INCOME (LOSS) TO ADJUSTED EBITDA (Unaudited) |
||||||||||||||||||||||||
(in millions) | Three Months Ended |
|||||||||||||||||||||||
Infrastructure | Life Sciences | Spectrum | Other and Eliminations | Non-operating Corporate |
HC2 | |||||||||||||||||||
Net loss attributable to |
$ | (4.7 | ) | |||||||||||||||||||||
Less: Net income attributable to HC2 Holdings Insurance Segment | 16.1 | |||||||||||||||||||||||
Less: Consolidating eliminations attributable to |
(0.9 | ) | ||||||||||||||||||||||
Net Income (loss) attributable to |
$ | 2.8 | $ | (5.7 | ) | $ | 9.1 | $ | (6.2 | ) | $ | (19.9 | ) | $ | (19.9 | ) | ||||||||
Adjustments to reconcile net income (loss) to Adjusted EBITDA: | ||||||||||||||||||||||||
Depreciation and amortization | 2.7 | — | 1.7 | — | — | 4.4 | ||||||||||||||||||
Depreciation and amortization (included in cost of revenue) | 2.2 | — | — | — | — | 2.2 | ||||||||||||||||||
Other operating (income) expense | 0.3 | — | (14.3 | ) | — | — | (14.0 | ) | ||||||||||||||||
Interest expense | 2.0 | — | 4.4 | — | 13.5 | 19.9 | ||||||||||||||||||
Loss on early extinguishment of debt | — | — | — | — | 0.2 | 0.2 | ||||||||||||||||||
Other (income) expense, net | 0.5 | (0.1 | ) | 1.7 | (0.4 | ) | 3.1 | 4.8 | ||||||||||||||||
Income tax (benefit) expense | 1.7 | — | 0.3 | 3.8 | (1.5 | ) | 4.3 | |||||||||||||||||
Noncontrolling interest | 0.4 | (2.2 | ) | (1.8 | ) | 0.3 | — | (3.3 | ) | |||||||||||||||
Discontinued operations | — | — | — | 5.1 | 0.1 | 5.2 | ||||||||||||||||||
Share-based payment expense | — | 0.1 | — | — | 0.2 | 0.3 | ||||||||||||||||||
Non-recurring items | 0.5 | — | — | — | 0.1 | 0.6 | ||||||||||||||||||
COVID-19 Costs | 4.2 | — | — | — | — | 4.2 | ||||||||||||||||||
Acquisition and disposition costs | 0.1 | — | — | 0.1 | 0.9 | 1.1 | ||||||||||||||||||
Adjusted EBITDA | $ | 17.4 | $ | (7.9 | ) | $ | 1.1 | $ | 2.7 | $ | (3.3 | ) | $ | 10.0 |
(in millions) | Three Months Ended |
||||||||||||||||||||||||
Infrastructure | Life Sciences | Spectrum | Other and Eliminations | Non-operating Corporate |
HC2 | ||||||||||||||||||||
Net loss attributable to |
$ | (31.0 | ) | ||||||||||||||||||||||
Less: Net loss attributable to |
(15.2 | ) | |||||||||||||||||||||||
Less: Consolidating eliminations attributable to |
(1.1 | ) | |||||||||||||||||||||||
Net Income (loss) attributable to |
$ | 6.7 | $ | (1.8 | ) | $ | (4.4 | ) | $ | 2.4 | $ | (17.6 | ) | $ | (14.7 | ) | |||||||||
Adjustments to reconcile net income (loss) to Adjusted EBITDA: | |||||||||||||||||||||||||
Depreciation and amortization | 3.7 | 0.2 | 1.6 | — | — | 5.5 | |||||||||||||||||||
Depreciation and amortization (included in cost of revenue) | 2.4 | — | — | — | — | 2.4 | |||||||||||||||||||
Other operating (income) expense | 0.6 | — | (0.2 | ) | 0.1 | — | 0.5 | ||||||||||||||||||
Interest expense | 2.3 | — | 3.3 | — | 14.4 | 20.0 | |||||||||||||||||||
Other (income) expense, net | (1.7 | ) | (0.3 | ) | 1.4 | 0.1 | (1.5 | ) | (2.0 | ) | |||||||||||||||
Income tax (benefit) expense | 2.9 | — | (1.6 | ) | — | (2.8 | ) | (1.5 | ) | ||||||||||||||||
Noncontrolling interest | 0.6 | (1.2 | ) | (1.1 | ) | 2.0 | — | 0.3 | |||||||||||||||||
Discontinued operations | — | — | — | (2.7 | ) | 2.8 | 0.1 | ||||||||||||||||||
Share-based payment expense | — | — | 0.1 | — | 1.5 | 1.6 | |||||||||||||||||||
Acquisition and disposition costs | 3.3 | — | (0.1 | ) | 0.1 | 0.5 | 3.8 | ||||||||||||||||||
Adjusted EBITDA | $ | 20.8 | $ | (3.1 | ) | $ | (1.0 | ) | $ | 2.0 | $ | (2.7 | ) | $ | 16.0 |
RECONCILIATION OF NET INCOME (LOSS) TO ADJUSTED EBITDA (Unaudited) |
||||||||||||||||||||||||
(in millions) | Twelve Months Ended |
|||||||||||||||||||||||
Infrastructure | Life Sciences | Spectrum | Other and Eliminations | Non-operating Corporate | HC2 | |||||||||||||||||||
Net loss attributable to |
$ | (92.0 | ) | |||||||||||||||||||||
Less: Net Income attributable to |
40.2 | |||||||||||||||||||||||
Less: Consolidating eliminations attributable to |
(6.0 | ) | ||||||||||||||||||||||
Net Income (loss) attributable to |
$ | 6.8 | $ | (14.4 | ) | $ | (17.5 | ) | $ | (1.5 | ) | $ | (99.6 | ) | $ | (126.2 | ) | |||||||
Adjustments to reconcile net income (loss) to Adjusted EBITDA: | ||||||||||||||||||||||||
Depreciation and amortization | 10.7 | 0.1 | 6.8 | — | 0.1 | 17.7 | ||||||||||||||||||
Depreciation and amortization (included in cost of revenue) | 9.1 | — | — | — | — | 9.1 | ||||||||||||||||||
Other operating (income) expenses | 0.1 | 0.1 | (6.7 | ) | — | — | (6.5 | ) | ||||||||||||||||
Interest expense | 8.5 | — | 14.7 | — | 56.2 | 79.4 | ||||||||||||||||||
Other (income) expense, net | 0.5 | (2.3 | ) | 5.7 | (72.2 | ) | 3.0 | (65.3 | ) | |||||||||||||||
Loss on early extinguishment of debt | — | — | — | — | 9.4 | 9.4 | ||||||||||||||||||
Income tax expense | 4.2 | — | 0.3 | 11.0 | 0.2 | 15.7 | ||||||||||||||||||
Noncontrolling interest | 0.6 | (6.2 | ) | (5.3 | ) | 0.8 | — | (10.1 | ) | |||||||||||||||
Discontinued operations | — | — | — | 61.7 | 3.9 | 65.6 | ||||||||||||||||||
Bonus to be settled in equity | — | — | — | — | (0.5 | ) | (0.5 | ) | ||||||||||||||||
Share-based payment expense | — | 0.2 | 0.3 | — | 2.4 | 2.9 | ||||||||||||||||||
Non-recurring items | 2.7 | — | — | — | 5.4 | 8.1 | ||||||||||||||||||
COVID-19 Costs | 19.4 | — | — | — | — | 19.4 | ||||||||||||||||||
Acquisition and disposition costs | 0.6 | — | 0.5 | 1.8 | 3.9 | 6.8 | ||||||||||||||||||
Adjusted EBITDA | $ | 63.2 | $ | (22.5 | ) | $ | (1.2 | ) | $ | 1.6 | $ | (15.6 | ) | $ | 25.5 |
(in millions) | Twelve Months Ended |
|||||||||||||||||||||||
Infrastructure | Life Sciences | Spectrum | Other & Elimination | Non-operating Corporate | HC2 | |||||||||||||||||||
Net loss attributable to |
$ | (31.5 | ) | |||||||||||||||||||||
Less: Net Income attributable to |
59.4 | |||||||||||||||||||||||
Less: Consolidating eliminations attributable to |
(8.7 | ) | ||||||||||||||||||||||
Net Income (loss) attributable to |
$ | 24.7 | $ | (0.2 | ) | $ | (18.5 | ) | $ | (0.6 | ) | $ | (87.6 | ) | $ | (82.2 | ) | |||||||
Adjustments to reconcile net income (loss) to Adjusted EBITDA: | ||||||||||||||||||||||||
Depreciation and amortization | 15.5 | 0.3 | 6.3 | — | 0.1 | 22.2 | ||||||||||||||||||
Depreciation and amortization (included in cost of revenue) | 9.1 | — | — | — | — | 9.1 | ||||||||||||||||||
Other operating (income) expenses | 0.5 | — | (2.9 | ) | 0.1 | — | (2.3 | ) | ||||||||||||||||
Interest expense | 9.3 | — | 9.6 | — | 57.5 | 76.4 | ||||||||||||||||||
Other (income) expense, net | (1.6 | ) | (8.6 | ) | 2.7 | — | 2.2 | (5.3 | ) | |||||||||||||||
Income tax (benefit) expense | 10.9 | — | (1.5 | ) | — | (8.1 | ) | 1.3 | ||||||||||||||||
Noncontrolling interest | 2.0 | (3.4 | ) | (3.8 | ) | 0.6 | — | (4.6 | ) | |||||||||||||||
Share-based payment expense | — | 0.1 | 0.6 | — | 5.5 | 6.2 | ||||||||||||||||||
Discontinued Operations | — | — | — | 3.5 | 11.0 | 14.5 | ||||||||||||||||||
Acquisition and disposition costs | 5.3 | — | 1.2 | 0.1 | 1.5 | 8.1 | ||||||||||||||||||
Adjusted EBITDA | $ | 75.7 | $ | (11.8 | ) | $ | (6.3 | ) | $ | 3.7 | $ | (17.9 | ) | $ | 43.4 |
RECONCILIATION OF NET INCOME (LOSS) TO ADJUSTED OPERATING INCOME ("INSURANCE AOI") AND PRE-TAX OPERATING INCOME ("PRE-TAX INSURANCE AOI") (Unaudited) |
||||||||||||||||||||||||
The table below shows the adjustments made to the reported Net income (loss) of the Insurance segment to calculate Insurance AOI and Pre-tax Insurance AOI. | ||||||||||||||||||||||||
(in millions) | Three Months Ended |
Twelve Months Ended |
||||||||||||||||||||||
2020 | 2019 | Increase / (Decrease) |
2020 | 2019 | Increase / (Decrease) |
|||||||||||||||||||
Net income (loss) - Insurance segment | $ | 16.1 | $ | (15.2 | ) | $ | 31.3 | $ | 40.2 | $ | 59.4 | $ | (19.2 | ) | ||||||||||
Effect of investment losses (gains) (1) | (4.7 | ) | 1.7 | (6.4 | ) | 13.6 | (1.9 | ) | 15.5 | |||||||||||||||
Asset impairment expense | — | 47.3 | (47.3 | ) | — | 47.3 | (47.3 | ) | ||||||||||||||||
Gain on bargain purchase | — | — | — | — | (1.1 | ) | 1.1 | |||||||||||||||||
Acquisition costs | — | 0.1 | (0.1 | ) | 0.1 | 2.1 | (2.0 | ) | ||||||||||||||||
Insurance AOI | 11.4 | 33.9 | (22.5 | ) | 53.9 | 105.8 | (51.9 | ) | ||||||||||||||||
Income tax expense (benefit) | 2.7 | (23.4 | ) | 26.1 | (4.3 | ) | (20.1 | ) | 15.8 | |||||||||||||||
Pre-tax Insurance AOI | $ | 14.1 | $ | 10.5 | $ | 3.6 | $ | 49.6 | $ | 85.7 | $ | (36.1 | ) | |||||||||||
(1) The Insurance segment results are inclusive of realized and unrealized gains and net investment income for the three and twelve months ended |
Source: HC2 Holdings, Inc.